Recent Data on the Use of SGLT2 Inhibitors for Heart Failure in Diabetic Patients

The treatment landscape for type 2 diabetes and heart failure has shifted dramatically with the emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors. Originally developed to lower blood glucose by promoting urinary glucose excretion, these agents have demonstrated striking cardiovascular benefits that extend well beyond glycemic control. Large-scale randomized controlled trials now provide robust evidence that SGLT2 inhibitors significantly reduce the risk of hospitalization for heart failure and cardiovascular death in patients with type 2 diabetes, and even in those without diabetes. This article reviews recent clinical data, underlying mechanisms, and practical implications for incorporating SGLT2 inhibitors into heart failure management for diabetic patients.

Overview of SGLT2 Inhibitors

SGLT2 inhibitors act on the proximal renal tubule, blocking the reabsorption of filtered glucose. This leads to glycosuria, reduced hyperglycemia, and modest weight loss. The class includes empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and the newer sotagliflozin (a dual SGLT1/SGLT2 inhibitor). All share a common mechanism but differ in selectivity, pharmacokinetics, and clinical trial data. Beyond glucose lowering, SGLT2 inhibitors induce natriuresis, reduce plasma volume, lower blood pressure, improve myocardial energetics, and decrease inflammation and oxidative stress. These pleiotropic effects likely account for their heart failure benefits independent of diabetes status.

Landmark Clinical Trials in Heart Failure with Reduced Ejection Fraction (HFrEF)

EMPEROR-Reduced Trial

The EMPEROR-Reduced trial (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction) randomized 3,730 patients with New York Heart Association (NYHA) class II–IV heart failure and left ventricular ejection fraction (LVEF) ≤40%. Approximately half had type 2 diabetes. Over a median follow-up of 16 months, empagliflozin 10 mg daily reduced the primary composite endpoint of cardiovascular death or hospitalization for heart failure by 25% (hazard ratio [HR] 0.75; 95% CI 0.65–0.86). The benefit was consistent in patients with and without diabetes. Additionally, the rate of decline in estimated glomerular filtration rate (eGFR) was slower in the empagliflozin group, confirming renal protective effects. These results were published in the New England Journal of Medicine in 2020 (EMPEROR-Reduced trial).

DAPA-HF Trial

The DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) enrolled 4,744 patients with HFrEF (LVEF ≤40%) and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP). Only 45% had type 2 diabetes. Dapagliflozin 10 mg daily reduced the primary composite of worsening heart failure (hospitalization or urgent visit) or cardiovascular death by 26% (HR 0.74; 95% CI 0.65–0.85). The benefit appeared early, within 4 weeks, and was sustained throughout the 18-month median follow-up. Key secondary outcomes, including total heart failure hospitalizations and all-cause mortality, also improved. The DAPA-HF results, published in 2019 (DAPA-HF trial), were instrumental in expanding the indication for dapagliflozin to include heart failure with reduced ejection fraction irrespective of diabetes status.

Extended Evidence in Heart Failure with Preserved Ejection Fraction (HFpEF)

EMPEROR-Preserved Trial

Heart failure with preserved ejection fraction (defined as LVEF ≥50%) has historically been challenging to treat. The EMPEROR-Preserved trial, including 5,988 patients (half with diabetes), demonstrated that empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 21% (HR 0.79; 95% CI 0.69–0.90). The benefit was driven primarily by a reduction in heart failure hospitalizations, with no significant effect on cardiovascular death alone. These findings, published in the New England Journal of Medicine in 2021 (EMPEROR-Preserved trial), marked the first major therapeutic advance for HFpEF and led to regulatory approval for this population.

DELIVER Trial

The DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) evaluated dapagliflozin in 6,263 patients with HFpEF (LVEF >40%, with a subset having mildly reduced EF 41–49%). Dapagliflozin reduced the primary endpoint of worsening heart failure or cardiovascular death by 18% (HR 0.82; 95% CI 0.73–0.92). The benefit was consistent across the ejection fraction spectrum, including those with LVEF 50% or greater. Combined with EMPEROR-Preserved, these data firmly establish SGLT2 inhibitors as foundational therapy for heart failure across all ejection fraction categories.

Real-World Evidence and Meta-Analyses

Large observational studies and meta-analyses support the trial findings. A 2023 meta-analysis of 13 randomized trials including over 90,000 patients confirmed that SGLT2 inhibitors reduce the risk of heart failure hospitalization by 28% and cardiovascular death by 14% in patients with diabetes. The benefits were additive to standard therapy including renin-angiotensin-aldosterone system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. Real-world data from the CVD-REAL and EMPRISE studies further demonstrated reduced heart failure hospitalization rates in clinical practice settings, reinforcing the generalizability of trial results.

Guideline Updates and Clinical Recommendations

Based on this evidence, major professional societies have updated their guidelines. The 2023 American Diabetes Association (ADA) Standards of Care recommend SGLT2 inhibitors with proven cardiovascular benefit (empagliflozin, dapagliflozin) for patients with type 2 diabetes and established or at high risk for heart failure. The 2021 European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure give a Class I recommendation (level of evidence A) for dapagliflozin or empagliflozin in patients with HFrEF regardless of diabetes status. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure similarly recommends SGLT2 inhibitors as first-line therapy for HFrEF and a reasonable option for HFpEF. These guidelines are available online (ADA Standards of Care and ESC Heart Failure Guidelines).

Safety Considerations and Practical Implementation

SGLT2 inhibitors are generally well tolerated, but clinicians must be aware of potential adverse effects. The most common are genital mycotic infections (especially in women) and volume depletion due to osmotic diuresis. Rare but serious risks include euglycemic diabetic ketoacidosis (eDKA), which can occur even with relatively normal blood glucose levels. Patients should be counseled to recognize symptoms such as nausea, vomiting, abdominal pain, and dyspnea. SGLT2 inhibitors should be temporarily discontinued during acute illness, surgery, or prolonged fasting. In heart failure patients, renal function and potassium should be monitored, though the risk of acute kidney injury is low when euvolemia is maintained. The drugs are not recommended in patients with eGFR <25 mL/min/1.73 m² at initiation (for empagliflozin and dapagliflozin) due to reduced efficacy for glycemic control, but renal benefit may still occur in those already on therapy who experience a decline.

Mechanisms Underlying Cardiovascular Benefit

The precise mechanisms by which SGLT2 inhibitors improve heart failure outcomes remain an area of active investigation. Proposed pathways include:

  • Hemodynamic effects: Natriuresis and plasma volume reduction decrease preload and myocardial wall stress, improving ventricular filling and reducing pulmonary congestion.
  • Metabolic effects: Enhanced ketone body utilization (particularly beta-hydroxybutyrate) provides an efficient fuel for the failing heart, improving myocardial energetics.
  • Anti-inflammatory and anti-fibrotic actions: Reduction in pro-inflammatory cytokines, oxidative stress, and cardiac fibrosis contributes to favorable remodeling.
  • Direct myocardial effects: Inhibition of the sodium-hydrogen exchanger (NHE-1) in cardiac myocytes reduces intracellular sodium and calcium overload, improving contractile function and reducing arrhythmia susceptibility.
  • Renal protection: Slowing progression of chronic kidney disease reduces cardiorenal syndrome and systemic volume overload.

These multifaceted effects collectively explain why SGLT2 inhibitors are effective across the full spectrum of heart failure, independent of ejection fraction or diabetes.

Implications for Clinical Practice in Diabetic Patients

For clinicians managing patients with type 2 diabetes and existing or high risk for heart failure, SGLT2 inhibitors should now be considered essential therapy. They offer dual benefits of glycemic control and cardiovascular risk reduction, often with minimal hypoglycemia risk when used without sulfonylureas or insulin. Key practical considerations include:

  1. Patient selection: All diabetic patients with HFrEF (LVEF ≤40%) should receive an SGLT2 inhibitor with proven benefit (empagliflozin or dapagliflozin). Those with HFpEF can also benefit. Even diabetic patients without established heart failure but with cardiovascular risk factors (age ≥55, prior CVD, albuminuria) may derive preventive benefit.
  2. Timing of initiation: Start early in the disease course. In patients hospitalized for acute decompensated heart failure, the EMPULSE trial showed that initiating empagliflozin during hospitalization is safe and improves clinical outcomes. The SOLOIST-WHF trial with sotagliflozin also demonstrated benefit post-discharge.
  3. Combination with other heart failure therapies: SGLT2 inhibitors are additive to neurohormonal blockade. In the EMPEROR-Reduced and DAPA-HF trials, >90% of patients were on ACE inhibitors/ARBs/ARNI, beta-blockers, and mineralocorticoid receptor antagonists. No significant drug interactions exist.
  4. Dosing and monitoring: Use standard once-daily oral doses (empagliflozin 10 mg, dapagliflozin 10 mg). Monitor renal function before and after initiation. Temporary discontinuation is recommended during intercurrent illness to avoid eDKA.
  5. Patient education: Counsel about genital hygiene, volume status, and signs of ketoacidosis. Advise against use during pregnancy or breastfeeding.

Future Directions

Ongoing research aims to clarify remaining questions. The EMPACT-MI trial is evaluating empagliflozin in patients with acute myocardial infarction to prevent incident heart failure. The DAPA-MI and EMPA-TROPISM trials are exploring effects in patients without diabetes already, and results continue to support broad efficacy. Studies are also investigating SGLT2 inhibitors in acute heart failure settings and in combination with novel agents like finerenone (a nonsteroidal mineralocorticoid receptor antagonist). The role of canagliflozin, which has shown renal benefits in the CREDENCE trial, is being explored further in the CHIEF-HF trial for heart failure outcomes. Additionally, the development of SGLT1/SGLT2 dual inhibitors may offer even greater benefits, especially in patients with reduced renal function. As evidence accumulates, it is likely that SGLT2 inhibitors will become a standard component of heart failure therapy irrespective of glycemic status, much like beta-blockers and ACE inhibitors.

Conclusion

Recent clinical data conclusively demonstrate that SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular mortality in patients with type 2 diabetes, with benefits extending to those without diabetes across the ejection fraction spectrum. The EMPEROR-Reduced, DAPA-HF, EMPEROR-Preserved, and DELIVER trials have transformed heart failure management. For diabetic patients, these medications offer a unique opportunity to simultaneously optimize glycemic control and cardiovascular outcomes. With strong guideline support and a favorable safety profile when appropriately monitored, SGLT2 inhibitors should be integrated into routine clinical care. Future research will further refine patient selection and elucidate the precise mechanisms driving these impressive benefits, solidifying the role of SGLT2 inhibition as a cornerstone of heart failure therapy.